Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Amicus Therapeutics, Inc. is a biotechnology company dedicated to developing innovative therapies for rare diseases, particularly Fabry and Pompe diseases. Its key products include Galafold®, the first oral treatment for Fabry disease, and Pombiliti® + Opfolda®, a dual therapy for Pompe disease. With a focus on precision medicine, Amicus aims to expand its market presence and enhance patient outcomes through ongoing research and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.